270 related articles for article (PubMed ID: 22972034)
1. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
Min DJ; Ezponda T; Kim MK; Will CM; Martinez-Garcia E; Popovic R; Basrur V; Elenitoba-Johnson KS; Licht JD
Leukemia; 2013 Mar; 27(3):686-94. PubMed ID: 22972034
[TBL] [Abstract][Full Text] [Related]
2. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
[TBL] [Abstract][Full Text] [Related]
3. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
Brito JL; Walker B; Jenner M; Dickens NJ; Brown NJ; Ross FM; Avramidou A; Irving JA; Gonzalez D; Davies FE; Morgan GJ
Haematologica; 2009 Jan; 94(1):78-86. PubMed ID: 19059936
[TBL] [Abstract][Full Text] [Related]
4. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
Ezponda T; Popovic R; Shah MY; Martinez-Garcia E; Zheng Y; Min DJ; Will C; Neri A; Kelleher NL; Yu J; Licht JD
Oncogene; 2013 Jun; 32(23):2882-90. PubMed ID: 22797064
[TBL] [Abstract][Full Text] [Related]
5. Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.
Ouyang Q; Chen G; Zhou J; Li L; Dong Z; Yang R; Xu L; Cui H; Xu M; Yi L
Neuro Oncol; 2016 Feb; 18(2):216-26. PubMed ID: 26180082
[TBL] [Abstract][Full Text] [Related]
6. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
Saha MN; Abdi J; Yang Y; Chang H
Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
[TBL] [Abstract][Full Text] [Related]
7. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
Shah MY; Martinez-Garcia E; Phillip JM; Chambliss AB; Popovic R; Ezponda T; Small EC; Will C; Phillip MP; Neri P; Bahlis NJ; Wirtz D; Licht JD
Oncogene; 2016 Nov; 35(45):5905-5915. PubMed ID: 27109101
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
Keats JJ; Maxwell CA; Taylor BJ; Hendzel MJ; Chesi M; Bergsagel PL; Larratt LM; Mant MJ; Reiman T; Belch AR; Pilarski LM
Blood; 2005 May; 105(10):4060-9. PubMed ID: 15677557
[TBL] [Abstract][Full Text] [Related]
9. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
[TBL] [Abstract][Full Text] [Related]
10. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
[TBL] [Abstract][Full Text] [Related]
11. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival.
Bommert KS; Effenberger M; Leich E; Küspert M; Murphy D; Langer C; Moll R; Janz S; Mottok A; Weissbach S; Rosenwald A; Bargou R; Bommert K
Leukemia; 2013 Feb; 27(2):441-50. PubMed ID: 22772059
[TBL] [Abstract][Full Text] [Related]
12. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.
Xie Z; Chooi JY; Toh SHM; Yang D; Basri NB; Ho YS; Chng WJ
Leukemia; 2019 Mar; 33(3):739-748. PubMed ID: 30470837
[TBL] [Abstract][Full Text] [Related]
13. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.
Marango J; Shimoyama M; Nishio H; Meyer JA; Min DJ; Sirulnik A; Martinez-Martinez Y; Chesi M; Bergsagel PL; Zhou MM; Waxman S; Leibovitch BA; Walsh MJ; Licht JD
Blood; 2008 Mar; 111(6):3145-54. PubMed ID: 18156491
[TBL] [Abstract][Full Text] [Related]
14. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
[TBL] [Abstract][Full Text] [Related]
15. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
16. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
[TBL] [Abstract][Full Text] [Related]
17. Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.
Zheng Y; Fornelli L; Compton PD; Sharma S; Canterbury J; Mullen C; Zabrouskov V; Fellers RT; Thomas PM; Licht JD; Senko MW; Kelleher NL
Mol Cell Proteomics; 2016 Mar; 15(3):776-90. PubMed ID: 26272979
[TBL] [Abstract][Full Text] [Related]
18. Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway.
Kuo CH; Chen KF; Chou SH; Huang YF; Wu CY; Cheng DE; Chen YW; Yang CJ; Hung JY; Huang MS
Carcinogenesis; 2013 Nov; 34(11):2600-9. PubMed ID: 23955539
[TBL] [Abstract][Full Text] [Related]
19. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
Lin TC; Lin PL; Cheng YW; Wu TC; Chou MC; Chen CY; Lee H
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1532-9. PubMed ID: 25990966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
